Physician profile
Stephen L Sutton
NPI 1972502359
$14,735.58
in general payments reported to CMS, 2019-2025
48 companies · $1,902 in 2025
The $1,902 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,413 · 2020: $1,168 · 2021: $1,914 · 2022: $2,655 · 2023: $2,859 · 2024: $2,824 · 2025: $1,902.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,585.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,584.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,236.95 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $1,673.92 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $1,513.01 | 2020-2025 | Ubrelvy, Qulipta, Vraylar |
| Glaxosmithkline, LLC. | $1,394.60 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Novo Nordisk INC | $1,278.56 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $960.03 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $878.74 | 2019-2025 | Jardiance |
| Abbott Laboratories | $701.19 | 2019-2025 | Freestyle Libre 3 |
| Amgen INC. | $614.23 | 2019-2025 | Evenity, Prolia, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $505.96 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $340.18 | 2021-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $334.17 | 2019-2024 | Trintellix |
| Janssen Pharmaceuticals, INC | $306.81 | 2019-2022 | |
| Astellas Pharma US INC | $265.64 | 2019-2025 | Veozah |
| Currax Pharmaceuticals LLC | $235.17 | 2020-2024 | Contrave, Nexlizet, Nexletol |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Sutton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.